• 4D Molecular Therapeutics highlighted 4D-150 as its lead program, targeting wet AMD, diabetic macular edema.
• Global Phase 3 program outlined for wet AMD, diabetic macular edema, positioning 4D-150 as a one-time intravitreal backbone anti-VEGF therapy.
• Phase 2b PRISM data cited for the Phase 3 dose, showing 1 mean supplemental injection through 1 year in the 3E10 vg/eye arm.
• Anti-VEGF market size cited at about USD 16 billion in 2025, including about USD 10 billion wet AMD, about USD 4 billion diabetic macular edema.
• Pipeline update included 4D-175 for geographic atrophy with an open IND, evaluating strategic funding alternatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.